Despite massive investment in research and development, the discovery of new drugs does not meet the demand for the reasonable treatment of most diseases affecting public health. The knowledge of human biology associated with pathologic conditions is still scarce to predict the drug targets.
CQMED was created in 2015 to contribute with molecular tools to tackle major challenges in the development of new drugs. CQMED executes a robust public/private partnership, including the academic and pharmaceutical industry.
CQMED is a member of:
- The National Science and Technology Institute – INCT funded by the Brazilian National Council for Scientific and Technological Development – CNPQ, Coordination for the Improvement of Higher Education Personnel – CAPES and FAPESP.
- The Brazilian Company of Research and Industrial Innovation – Embrapii
CQMED research projects are executed by a team of molecular, structural, and cell biologists, biochemists, medicinal chemists, and geneticists. The major focus is the development of chemical probes for new targets associated with cancer, rare and infectious diseases.